SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)
$2.53 -0.06 (-2.3166%)
Analysed SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) News Sources
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
05-07-2026
yahoo.com
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
15-07-2026
yahoo.com
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
30-07-2026
yahoo.com
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
06-08-2026
yahoo.com
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
06-08-2026
yahoo.com
SAB Biotherapeutics Q2 Earnings Call Highlights
07-08-2026
marketbeat.com
SAB BIO to Participate in Upcoming Investor Conferences
01-09-2026
yahoo.com
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
22-09-2026
yahoo.com
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
13-10-2026
yahoo.com
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
14-10-2026
yahoo.com
What is the current price of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The current price of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is $2.53.
SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) absolute price change since previous trading day?
The absolute price change of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) since the previous trading day is $-0.06.
SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) percentage price change since previous trading day?
The percentage price change of SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) since the previous trading day is -2.3166%.
What is the most recent average sentiment score for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The most recent average sentiment score for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)?
The most recent sentiment for SAB BIOTHERAPEUTICS INC (SABS:NASDAQ) is .
SEC-8K** Filing Available For SAB BIOTHERAPEUTICS INC (SABS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.